Why the study?
The lack of an FDA-approved percutaneous valve technology for severe aortic regurgitation presents a clinical challenge in high-risk patients.
Answers are grounded in this paper and cite their sources.
Transcatheter aortic valve replacement using a self-expanding valve may be a feasible off-label treatment option for severe aortic regurgitation in high-risk patients.
The absence of a Food and Drug Administration-approved percutaneous valve technology for the treatment of severe aortic regurgitation (AR) presents a challenge for high-risk patients. In this report, we describe the successful treatment of an 84-year-old male patient suffering from severe symptomatic AR and concomitant cardiorenal syndrome with renal failure using a 34 mm Evolut R (Medtronic) self-expanding transcatheter aortic valve replacement. This intervention resulted in the resolution of AR, cardiorenal syndrome, and congestive heart failure symptoms.
No takes yet. Share an insight, caveat, or question.
Mutlu et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: